	US 11,884,634 B2
	Compositions of solid forms of (S)-2-(((S)-6,8-difluoro-1,2,3,4- tetrahydronaphthalen-2-yl)amino)-N-(1-(2-methyl-1-(neopentylamino)propan-2-yl)-1H-imidazol-4-yl)pentanamide
Elaine Greer, Groton, CT (US); Stephen Anderson, Stonington, CT (US); Mark Maloney, Groton, CT (US); Shu Yu, Groton, CT (US); Ekaterina Albert, West Lafayette, IN (US); and Emily Rigsbee, West Lafayette, IN (US)
Assigned to PFIZER INC., New York, NY (US)
Filed by Pfizer Inc., New York, NY (US)
Filed on Nov. 21, 2022, as Appl. No. 18/057,633.
Application 16/886,622 is a division of application No. 16/818,863, filed on Mar. 13, 2020, granted, now 10,710,966, issued on Jul. 14, 2020.
Application 16/818,863 is a division of application No. 16/537,394, filed on Aug. 9, 2019, granted, now 10,590,087, issued on Mar. 17, 2020.
Application 18/057,633 is a continuation of application No. 17/180,296, filed on Feb. 19, 2021, granted, now 11,566,006.
Application 17/180,296 is a continuation of application No. 16/886,622, filed on May 28, 2020, granted, now 10,941,118, issued on Mar. 9, 2021.
Prior Publication US 2023/0147121 A1, May 11, 2023
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 31/40 (2006.01); C07D 233/88 (2006.01); A61P 21/00 (2006.01)

CPC C07D 233/88 (2013.01) [A61P 21/00 (2018.01); A61K 31/40 (2013.01); C07B 2200/13 (2013.01)]

6 Claims

1. A pharmaceutical composition comprising a solid form of a hydrobromide salt of (S)-2-(((S)-6,8-difluoro-1,2,3,4-tetrahydronaphthalen-2-yl)amino)-N-(1-(2-methyl-1-(neopentylamino) propan-2-yl)-1H-imidazol-4-yl)pentanamide, wherein the solid form is characterized by a differential scanning calorimetry profile comprising a phase transition at a temperature selected from about 39, 65, 69, 80, 87, 122, 139, 143, 152, 157, 160, 213, 222, 223, 230, and 274° C.